Skip to main
BBNX

BBNX Stock Forecast & Price Target

BBNX Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 55%
Buy 27%
Hold 18%
Sell 0%
Strong Sell 0%

Bulls say

Beta Bionics Inc. has demonstrated a strong financial performance and growth potential, as evidenced by a 63.3% year-over-year increase in Q3 revenue, totaling $27.3 million, which exceeded previous estimates. The company has also updated its revenue forecasts, raising estimates for 2025 and 2026 to $97.5 million and $136 million, respectively, reflecting strong momentum from new patient starts, particularly through the pharmacy channel. Additionally, Beta Bionics is successfully expanding its market presence, with 70% of new patient starts coming from conversions from multiple daily injections, which is expected to drive robust, higher-margin sales growth in the coming years.

Bears say

Beta Bionics Inc faces significant risks that contribute to a negative outlook on its stock, including challenges in gaining meaningful market share for its iLet product amid competitive pressures and potential delays in clinical development timelines. The company's financial performance is under scrutiny due to an EBITDA loss of $12.2 million, substantially exceeding previous estimates, highlighting operational inefficiencies and a sluggish sales force ramp-up. Additionally, the implications of evolving Medicare reimbursement policies and the anticipated need for additional capital could exert downward pressure on revenue, profitability, and shareholder value, creating a complex financial landscape for the company.

BBNX has been analyzed by 11 analysts, with a consensus rating of Buy. 55% of analysts recommend a Strong Buy, 27% recommend Buy, 18% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Beta Bionics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Beta Bionics Inc (BBNX) Forecast

Analysts have given BBNX a Buy based on their latest research and market trends.

According to 11 analysts, BBNX has a Buy consensus rating as of Feb 7, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $27.36, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $27.36, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Beta Bionics Inc (BBNX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.